HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD-AND-NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD-AND-NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD-AND-NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Voice-Saving cancer trial: which chemo regimen works best?
Disease control OngoingThis phase 3 trial tests two chemotherapy strategies to preserve larynx function in 256 patients with advanced larynx or hypopharynx cancer. One group gets induction chemo (TPF) followed by radiation; the other gets radiation with cisplatin. The main goal is to see which approach…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated May 17, 2026 01:01 UTC
-
New antibody drug shows promise in early cancer trial
Disease control OngoingThis early-stage study tests a new drug called IMT-009 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. About 67 participants will receive the drug intravenously,…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Immunitas Therapeutics • Aim: Disease control
Last updated May 17, 2026 01:01 UTC
-
New combo therapy aims to shrink head and neck tumors in phase 2 trial
Disease control OngoingThis study tests whether adding an experimental drug (domvanalimab) to a standard immunotherapy (zimberelimab) plus chemotherapy works better than the standard immunotherapy plus chemotherapy alone for people with head and neck cancer that has spread or returned and cannot be cur…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated May 17, 2026 01:00 UTC
-
Experimental cell therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an investigational cell therapy called P-MUC1C-ALLO1 in adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The main goals are to find a safe dose and check for early sign…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:53 UTC
-
New hope for tough cancers: experimental drug targets tumors resistant to standard therapy
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 1,410 participants will receive t…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated May 17, 2026 00:53 UTC
-
New combo therapy targets tough head and neck cancers
Disease control OngoingThis study tests a new drug, SI-B001, combined with paclitaxel in 42 adults with head and neck cancer that has returned or spread. Participants have already tried standard treatments. The goal is to see if the combination shrinks tumors and is safe. This is not a cure, but aims t…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
Cancer combo trial pulled before it even started
Disease control TerminatedThis study planned to test a new drug (TTI-101) combined with an existing immunotherapy (pembrolizumab) for people with advanced head and neck cancer that had come back or spread. The goal was to see if the combination was safe and could shrink tumors. However, the study was with…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
New drug RPH-002 takes on erbitux in head and neck cancer showdown
Disease control OngoingThis study tests whether a new drug called RPH-002 works as well as the standard drug Erbitux for people with advanced head and neck cancer that has spread or come back. About 161 participants will receive either RPH-002 or Erbitux along with chemotherapy. The main goal is to see…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: R-Pharm • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
New Vaccine-Immunotherapy combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase study tested a vaccine (p53MVA) plus the drug pembrolizumab in 11 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the combination is safe and can boost the immune system to attack cancer cells. Participant…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 00:49 UTC
-
New combo aims to boost immunotherapy for head and neck cancer
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard immunotherapy (pembrolizumab) helps people with head and neck cancer that has returned or spread. About 52 adults with incurable, measurable disease will receive either the combo or pembrolizumab alone. The goal is …
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
New combo therapy aims to shrink Hard-to-Treat tumors
Disease control OngoingThis study tests an experimental drug (ARRY-614) combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds the safest dose, and the second part checks i…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
New combo therapy aims to stop head and neck cancer relapse
Disease control OngoingThis study tests whether adding lenvatinib to pembrolizumab (immunotherapy) after standard chemoradiation helps prevent head and neck cancer from coming back. About 50 adults with advanced PD-L1 positive cancer will receive either the combination or pembrolizumab alone as mainten…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated May 15, 2026 12:07 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called sEphB4-HSA alongside standard chemotherapy in people with advanced or metastatic solid tumors (like head and neck, pancreatic, lung, and gallbladder cancers). The main goals are to find the best dose and check for side effects. About…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Immunotherapy may replace chemo in head and neck cancer treatment
Disease control OngoingThis study tests whether the immunotherapy drug pembrolizumab (Keytruda) combined with radiation works better than standard chemotherapy (cisplatin) plus radiation for people with advanced head and neck cancer. About 126 participants with p16-positive cancer will be randomly assi…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Loren Mell, MD • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug duo aims to shrink head and neck tumors
Disease control OngoingThis study tests two different schedules of the experimental drug FID-007 combined with cetuximab in 46 adults with advanced head and neck cancer that has spread or come back. The goal is to see which dosing works better at shrinking tumors and to check for side effects. Particip…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New antibody drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called MCLA-129 in people with advanced lung, stomach, esophageal, head/neck, or colorectal cancers that have not responded to standard treatments. The drug is a bispecific antibody designed to attack two cancer-related targets at once. The goal is to …
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for head and neck cancer: drug combo trial launches
Disease control OngoingThis study tests whether combining the drug tislelizumab with other experimental drugs can shrink tumors or slow cancer growth in people with advanced head and neck cancer that has come back or spread. About 160 adults whose cancer cannot be cured with local treatments will recei…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug candidate ABBV-400 takes on eight tough cancers
Disease control OngoingThis early-phase study tests an experimental drug called ABBV-400 in about 302 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The main goals are to check safety, side effects, and whether the drug shrinks tumors. Participants receive …
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New cocktail aims to tame untreatable head and neck cancer
Disease control OngoingThis study tests a three-drug combination called CACTUX (cisplatin, nab-paclitaxel, and cetuximab) in 74 adults with incurable head and neck cancer that has spread or come back. The goal is to see how well the treatment controls the disease and what side effects occur. Participan…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy aims to reignite immune attack on tough cancers
Disease control OngoingThis study is for people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease has progressed after standard immunotherapy. It tests a new drug combination designed to boost the immune system to fight cancer. About 40 participants will receive the experime…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New combo therapy aims to reignite immune attack on resistant cancers
Disease control OngoingThis study tests a combination of three treatments—an immune-boosting drug injected into a tumor (IL-2), targeted radiation, and the immunotherapy pembrolizumab—in adults with advanced lung, skin, kidney, or head-and-neck cancers that no longer respond to standard immunotherapy. …
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug cocktail targets tough head and neck tumors
Disease control OngoingThis early-phase study tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation for people with advanced head and neck cancer that has spread to nearby tissues or lymph nodes. The main goal is to find the safest dose and understand sid…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
HPV vaccine combo shows promise in shrinking head and neck tumors before surgery
Disease control OngoingThis study tests whether combining an HPV DNA vaccine with other drugs can shrink tumors in people with advanced head and neck cancer caused by HPV types 16 or 18. Participants receive the treatment before surgery, and doctors check how much of the tumor is killed. The goal is to…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for head and neck cancer patients who failed standard treatments
Disease control OngoingThis study tests a new drug called SI-B001 in 11 adults with advanced head and neck cancer that has returned or spread. Participants have already tried standard treatments like immunotherapy and chemotherapy without success. The goal is to see if SI-B001 can shrink tumors and how…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New triple therapy aims to control hard-to-treat head and neck cancer
Disease control OngoingThis early-stage study tests a new drug (INCB081776) combined with standard immunotherapy (pembrolizumab) and palliative radiation in 10 people whose head and neck cancer has returned or spread. The main goal is to check safety and side effects. Researchers will also see if the t…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Immunotherapy plus chemo shows promise against tough head and neck cancers
Disease control OngoingThis study tests whether adding an immunotherapy drug (treprizumab) to standard chemotherapy before surgery can improve outcomes for people with locally advanced head and neck cancer. 122 participants are randomly assigned to receive either the combination or chemotherapy alone f…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug combo shows promise in shrinking head and neck tumors before surgery
Disease control OngoingThis study tests whether giving two drugs—nivolumab and BMS-986253—before surgery can safely shrink tumors in people with head and neck cancer. About 24 adults with HPV-negative squamous cell carcinoma will receive the combination before their planned surgery. The main goals are …
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Radiation plus immunotherapy shows promise against tough head and neck cancers
Disease control OngoingThis study tests whether giving a short course of radiation plus an immunotherapy drug (pembrolizumab) before surgery can shrink advanced head and neck cancers. About 28 adults with stage III or IV HPV-negative head and neck cancer will receive this neoadjuvant treatment. The mai…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New combo therapy aims to extend life without sacrificing quality in advanced head and neck cancer
Disease control OngoingThis study looks at adults with head and neck cancer that has spread to a few other spots (up to 3). It compares two treatments: stereotactic radiotherapy alone versus the same radiation plus chemotherapy. The goal is to see which approach helps people live longer with a good qua…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New combo therapy aims to shrink hard-to-treat head and neck tumors
Disease control OngoingThis study tests a new drug called NT219 combined with either pembrolizumab or cetuximab in people with head and neck cancer that has come back or spread. The goal is to see if the combination can shrink tumors. About 29 adults with incurable head and neck squamous cell carcinoma…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New drug combo shows promise in shrinking tumors before surgery
Disease control OngoingThis study tests whether giving the drug cemiplimab (alone or with fianlimab) before surgery can shrink tumors in people with lung, liver, or head/neck cancers. About 65 participants will receive the drug and then have surgery to remove their cancer. Researchers will check how mu…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Immune-Boosting cocktail aims to shrink head and neck tumors before surgery
Disease control OngoingThis early-phase study tests whether combining two immune-boosting drugs (CD40 agonist and PD-1 inhibitor) before surgery can help shrink HPV-negative head and neck cancers. About 27 adults with resectable tumors will receive the drugs, then undergo surgery to remove the cancer. …
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New dual-immunotherapy combo tested in advanced cancers
Disease control OngoingThis early-phase study tests a new drug, AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment for people with advanced solid tumors that have stopped responding to standard therapies. The main goal is to find the safest dose and check for…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
Blood test may help personalize chemo for head and neck cancer patients
Disease control TerminatedThis study tests whether a blood test that tracks tumor DNA can help doctors decide when to add short bursts of chemotherapy to standard immunotherapy for people with head and neck cancer that has returned or spread. About 30 adults will receive the immunotherapy drug pembrolizum…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New combo therapy aims to supercharge immune cells against cancer
Disease control OngoingThis study tests whether combining the immunotherapy drug pembrolizumab with the diabetes drug metformin can help shrink tumors in people with advanced head and neck cancer that has spread or come back. The goal is to boost the body's natural killer cells to fight the cancer more…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Trisha Wise-Draper • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
Which chemo combo works best for head and neck cancer?
Disease control OngoingThis study compares two different chemotherapy drug combinations to find out which is more effective for treating advanced head and neck cancer that hasn't been treated before. About 128 adults with stage IV cancer of the throat, mouth, or voice box will receive one of the two co…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors, including bladder, breast, lung, and other cancers. The goal is to find a safe and effective dose and see if the drug can shrink tumors. About 490 participants will take p…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 05, 2026 11:52 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests an experimental drug called HFB200301, alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The main goal is to find safe doses and check for side effects. About 72 people will take part, and the st…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated May 04, 2026 16:31 UTC
-
Triple threat: vaccine, immunotherapy, and Chemo-Radiation take on HPV head and neck cancer
Disease control OngoingThis study tests a new treatment for a type of head and neck cancer caused by HPV. It combines a vaccine that targets the cancer cells, an immunotherapy drug (pembrolizumab), and standard chemo-radiation. The goal is to see if this combination can better control the cancer and pr…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated May 04, 2026 16:20 UTC
-
New combo therapy targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 120 people with various canc…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: NeoTX Therapeutics Ltd. • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New three-step combo therapy targets tough head and neck cancers
Disease control OngoingThis study tests a three-step treatment plan for people with a type of head and neck cancer not linked to HPV. First, patients receive a drug called palbociclib before standard chemoradiation, then they get more palbociclib after treatment. The goal is to see if this approach hel…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New Light-Based scanner could spot hidden cancer spread in neck
Diagnosis TerminatedThis study tests a new imaging tool called MSOT that uses light and sound to create detailed pictures of neck lymph nodes in people with head and neck cancer. The goal is to see if it can more accurately find cancer that has spread to lymph nodes and also detect tissue damage fro…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated May 13, 2026 16:02 UTC
-
AI-Powered watchdog aims to keep cancer patients out of the ER
Symptom relief OngoingThis study tests whether using a machine learning program to closely monitor symptoms can help head and neck cancer patients avoid urgent hospital visits during radiation therapy. About 72 adults with non-spreading head and neck cancer will either receive standard care or extra s…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated May 17, 2026 00:52 UTC
-
Which Follow-Up schedule saves more lives after head and neck cancer?
Knowledge-focused OngoingThis study looks at whether a more intensive follow-up schedule after head and neck cancer treatment helps people live longer compared to a standard schedule. It involves 197 smokers or heavy drinkers over age 35 who are cancer-free 2-4 months after treatment. Researchers will tr…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated May 17, 2026 00:49 UTC
-
3D tumor maps could sharpen radiation targeting in head and neck cancer
Knowledge-focused OngoingThis study explores whether creating a virtual 3D map of a patient's tumor can help doctors plan radiation therapy more accurately for head and neck cancer. About 13 adults who have had surgery for head and neck cancer will participate. Researchers will compare standard radiation…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC
-
Cancer test study pulled before it even started
Knowledge-focused TerminatedThis study planned to check if a special test, called OncoPrism-HNSCC, could predict how well immunotherapy would work in people with head and neck cancer. Researchers wanted to compare test results with actual treatment outcomes. However, the study was withdrawn before enrolling…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Sponsor: Cofactor Genomics, Inc. • Aim: Knowledge-focused
Last updated May 13, 2026 15:59 UTC